Supernus Pharmaceuticals, Inc. has successfully completed its merger with Indivior Pharmaceuticals, Inc., which will now operate under the name Supernus, Inc. This merger, effective November 2, 2026, represents a notable shift in the pharmaceutical industry, particularly in the realm of pharmaceutical preparations.

The merger was formalized through an agreement dated August 1, 2026, where Artemis Merger Sub Inc. merged with Supernus Pharmaceuticals, making it a wholly-owned subsidiary of Indivior. As part of this transaction, each outstanding share of Supernus Pharmaceuticals common stock was canceled and converted into the right to receive 1.5401 shares of Indivior common stock.

According to the recent SEC filing (accession number 0001256088-26-000008), the reporting owner, Georges Gemayel, a director at Supernus, reported the disposition of 27,277 shares of Supernus Pharmaceuticals common stock as a result of this merger. Additionally, he acquired 2,989 restricted stock units and 6,036 stock options as part of the new equity awards under the merged entity.

This merger is expected to impact various stakeholders, including shareholders and employees of both companies, as they navigate the integration of operations and corporate cultures. The merger enhances Indivior's position in the pharmaceutical market, potentially leading to increased market share and expanded product offerings.

Moving forward, the industry will be watching how Supernus, now part of Indivior, leverages this merger to enhance its product pipeline and operational efficiencies. The filing does not specify what happens next, but the implications of this merger are likely to unfold in the coming months as the companies integrate their operations.